Clinical Trials Logo

Filter by:
NCT ID: NCT05727540 Recruiting - Uveitis Clinical Trials

The Cohort Study of Uveitis Patients

Start date: February 20, 2023
Phase:
Study type: Observational

This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.

NCT ID: NCT05727397 Recruiting - Clinical trials for Wet Age-related Macular Degeneration

Efficacy and Safety of RC28-E Versus Aflibercept

Start date: March 14, 2023
Phase: Phase 3
Study type: Interventional

This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.

NCT ID: NCT05727358 Completed - Clinical trials for Acute Stroke Patients With Depression

Effectiveness of Group Acceptance and Commitment Therapy in Treating Acute Stroke Patients With Depression

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to discover the effectiveness of group-based Acceptance and Commitment Therapy (ACT) in treating depression for acute stroke patients. The main question[s] it aims to answer are: - Group-based ACT (G-ACT) could significantly reduce the depressive symptoms in patients with acute stroke, - the interventional efficacy could be maintained at 3-month follow-up - similar benefits would be observed for quality of life (QOL), sleep quality, psychological flexibility, cognitive fusion, and confidence. The patients included to the control group received usual care support in hospital, and the patients included to the intervention group received G-ACT and usual care support. the G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.

NCT ID: NCT05727293 Completed - Sepsis Bacterial Clinical Trials

A Case Report of a Patient With Intellectual Disability and Neurogenic Bladder Complicated With Sepsis

Start date: September 6, 2022
Phase:
Study type: Observational

A case report of a patient with intellectual disability and neurogenic bladder complicated with sepsis

NCT ID: NCT05727176 Recruiting - Clinical trials for Advanced Cholangiocarcinoma

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

FOENIX-CCA4
Start date: May 12, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.

NCT ID: NCT05727163 Recruiting - Clinical trials for Colorectal Cancer Metastatic

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Start date: July 29, 2022
Phase: Phase 2
Study type: Interventional

This prospective, randomized, controlled clinical study aims to evaluate the objective remission rate of FOLFOX hepatic artery infusion chemotherapy (HAI) in combination with systemic irinotecan with or without bevacizumab versus systemic intravenous FOLFOXIRI with or without bevacizumab in initially unresectable RAS-mutated colorectal cancer patients with liver metastases.

NCT ID: NCT05727085 Recruiting - Twin Pregnancy Clinical Trials

Cohort of Twin Pregnancy and the Offspring

CTPO
Start date: July 2023
Phase:
Study type: Observational

Twin pregnancy increases the risk of maternal and fetal complications, which include gestational hypertension, premature labor, twin-to-twin transfusion syndrome, intrauterine growth restriction, anemia, amniotic fluid abnormalities. Comprehensively understanding the molecular mechanisms of the disease and identification of markers contribute to development of novel therapeutic approaches. In addition, the twin pregnancy, especially the monochorionic, is an essential model of "experiments of nature". This model can be applied to distinguish the epigenetic differences of twins in utero and after birth in the same genomic context. The aim of the study is to constitute a prospective cohort of twin pregnancies and the offspring.

NCT ID: NCT05726734 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial

Start date: February 6, 2023
Phase: Phase 4
Study type: Interventional

Vonoprazan Amoxicillin and metronidazole based triple therapy had achieved a high cure rate in the rescue treatment of helicobacter pylori infection. This study aims to evaluate the efficacy and safety of the Vonoprazan, amoxicillin and metronidazole based triple therapy and the empiric bismuth quadruple therapy in the naive patients with Helicobacter pylori infection.

NCT ID: NCT05726461 Recruiting - Diabetes Mellitus Clinical Trials

Efficacy and Safety of Android Artificial Pancreas System in Adult Patients With Type 1 Diabetes Mellitus in China

Start date: February 11, 2023
Phase: N/A
Study type: Interventional

This is a 26-week randomized, free-living, open-label, two-arm, two-phase, crossover trial. Participants will receive two interventions at different phases, including the Android artificial pancreas system(AndroidAPS-rt-CGM) and sensor-augment pump(SAP), and use marketed rapid-acting insulin analogs (insulin Aspart, insulin Lispro, or insulin Glulisine) normally used in their usual clinical care. The safety and efficacy of AndroidAPS-rt-CGM and SAP in adult T1DM with suboptimal glycemic control will be compared to explore whether the use of AndroidAPS-rt-CGM in adult T1DM with suboptimal glycemic control will be associated with better glycemic control with no increased hypoglycemia.

NCT ID: NCT05726175 Not yet recruiting - Breast Cancer Clinical Trials

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Disitamab Vedotin combined with Penpulimab as neoadjuvant therapy in patients with HER2-low early or locally advanced breast cancer